Literature DB >> 14752736

4-dimensional computed tomography imaging and treatment planning.

Paul Keall1.   

Abstract

In the era of conformal therapy and intensity-modulated therapy, there is an increased desire to raise tumor dose to facilitate improved survival and decrease normal tissue dose to reduce treatment-related complications. Setup accuracy and internal motion limit our ability to reduce margins. Internal motion has both interfraction and intrafraction components, although only the intrafraction component will be addressed here. Intrafraction motion is significant for lung, liver, and pancreatic radiotherapy and to a lesser extent breast and prostate radiotherapy. A method to explicitly account for intrafraction motion is to temporally adjust the treatment beam based on the tumor position with time such that the motion of the radiation beam is synchronized with the tumor motion. This addition of time into the 3-dimensional treatment process is termed 4-dimensional (4D) radiotherapy. Four-dimensional radiotherapy may allow safe clinical target volume-planning target volume margin reduction to achieve the goals of raised tumor dose and decreased normal tissue dose. This article discusses methodology for 4D CT imaging and 4D treatment planning, with some comments on 4D radiation delivery.

Entities:  

Mesh:

Year:  2004        PMID: 14752736     DOI: 10.1053/j.semradonc.2003.10.006

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  110 in total

1.  Four-dimensional magnetic resonance imaging (4D-MRI) using image-based respiratory surrogate: a feasibility study.

Authors:  Jing Cai; Zheng Chang; Zhiheng Wang; William Paul Segars; Fang-Fang Yin
Journal:  Med Phys       Date:  2011-12       Impact factor: 4.071

Review 2.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

3.  4D Cone-beam CT reconstruction using a motion model based on principal component analysis.

Authors:  David Staub; Alen Docef; Robert S Brock; Constantin Vaman; Martin J Murphy
Journal:  Med Phys       Date:  2011-12       Impact factor: 4.071

4.  A method to evaluate dose errors introduced by dose mapping processes for mass conserving deformations.

Authors:  C Yan; G Hugo; F J Salguero; N Saleh-Sayah; E Weiss; W C Sleeman; J V Siebers
Journal:  Med Phys       Date:  2012-04       Impact factor: 4.071

5.  Extraction of tumor motion trajectories using PICCS-4DCBCT: a validation study.

Authors:  Zhihua Qi; Guang-Hong Chen
Journal:  Med Phys       Date:  2011-10       Impact factor: 4.071

6.  Practical approaches to four-dimensional heavy-charged-particle lung therapy.

Authors:  Shinichiro Mori; Ziji Wu; Michael R Folkert; Motoki Kumagai; Suguru Dobashi; Toshio Sugane; Masayuki Baba
Journal:  Radiol Phys Technol       Date:  2009-10-14

Review 7.  Magnetic resonance imaging in lung: a review of its potential for radiotherapy.

Authors:  Shivani Kumar; Gary Liney; Robba Rai; Lois Holloway; Daniel Moses; Shalini K Vinod
Journal:  Br J Radiol       Date:  2016-02-03       Impact factor: 3.039

8.  A post-processing method based on interphase motion correction and averaging to improve image quality of 4D magnetic resonance imaging: a clinical feasibility study.

Authors:  Zixin Deng; Jianing Pang; Yi Lao; Xiaoming Bi; Guan Wang; Yuhua Chen; Matthias Fenchel; Richard Tuli; Debiao Li; Wensha Yang; Zhaoyang Fan
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

9.  Frequency-Selective Computed Tomography: Applications During Periodic Thoracic Motion.

Authors:  Jacob Herrmann; Eric A Hoffman; David W Kaczka
Journal:  IEEE Trans Med Imaging       Date:  2017-04-18       Impact factor: 10.048

10.  Four-dimensional deformable image registration using trajectory modeling.

Authors:  Edward Castillo; Richard Castillo; Josue Martinez; Maithili Shenoy; Thomas Guerrero
Journal:  Phys Med Biol       Date:  2010-01-07       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.